These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

227 related items for PubMed ID: 21964956

  • 1. Sirolimus-based immunosuppression in liver transplantation for hepatocellular carcinoma: a meta-analysis.
    Liang W, Wang D, Ling X, Kao AA, Kong Y, Shang Y, Guo Z, He X.
    Liver Transpl; 2012 Jan; 18(1):62-9. PubMed ID: 21964956
    [Abstract] [Full Text] [Related]

  • 2. Sirolimus-based immunosuppression therapy in liver transplantation for patients with hepatocellular carcinoma exceeding the Milan criteria.
    Zhou J, Wang Z, Wu ZQ, Qiu SJ, Yu Y, Huang XW, Tang ZY, Fan J.
    Transplant Proc; 2008 Dec; 40(10):3548-53. PubMed ID: 19100435
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus in liver transplant recipients: a large single-center experience.
    Vivarelli M, Dazzi A, Cucchetti A, Gasbarrini A, Zanello M, Di Gioia P, Bianchi G, Tamè MR, Gaudio MD, Ravaioli M, Cescon M, Grazi GL, Pinna AD.
    Transplant Proc; 2010 Sep; 42(7):2579-84. PubMed ID: 20832548
    [Abstract] [Full Text] [Related]

  • 4. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma.
    Vivarelli M, Dazzi A, Zanello M, Cucchetti A, Cescon M, Ravaioli M, Del Gaudio M, Lauro A, Grazi GL, Pinna AD.
    Transplantation; 2010 Jan 27; 89(2):227-31. PubMed ID: 20098287
    [Abstract] [Full Text] [Related]

  • 5. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma.
    Kneteman NM, Oberholzer J, Al Saghier M, Meeberg GA, Blitz M, Ma MM, Wong WW, Gutfreund K, Mason AL, Jewell LD, Shapiro AM, Bain VG, Bigam DL.
    Liver Transpl; 2004 Oct 27; 10(10):1301-11. PubMed ID: 15376305
    [Abstract] [Full Text] [Related]

  • 6. Sirolimus therapy in liver transplant patients: an initial experience at a single center.
    Nocera A, Andorno E, Tagliamacco A, Morelli N, Bottino G, Ravazzoni F, Casaccia M, Barocci S, Alice S, Santori G, Ghirelli R, Valente U.
    Transplant Proc; 2008 Oct 27; 40(6):1950-2. PubMed ID: 18675098
    [Abstract] [Full Text] [Related]

  • 7. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects.
    Toso C, Meeberg GA, Bigam DL, Oberholzer J, Shapiro AM, Gutfreund K, Ma MM, Mason AL, Wong WW, Bain VG, Kneteman NM.
    Transplantation; 2007 May 15; 83(9):1162-8. PubMed ID: 17496530
    [Abstract] [Full Text] [Related]

  • 8. Effects of maintenance immunosuppression with sirolimus after liver transplant for hepatocellular carcinoma.
    Yanik EL, Chinnakotla S, Gustafson SK, Snyder JJ, Israni AK, Segev DL, Engels EA.
    Liver Transpl; 2016 May 15; 22(5):627-34. PubMed ID: 26784951
    [Abstract] [Full Text] [Related]

  • 9. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.
    Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM.
    Hepatology; 2010 Apr 15; 51(4):1237-43. PubMed ID: 20187107
    [Abstract] [Full Text] [Related]

  • 10. Meta-analysis: recurrence and survival following the use of sirolimus in liver transplantation for hepatocellular carcinoma.
    Menon KV, Hakeem AR, Heaton ND.
    Aliment Pharmacol Ther; 2013 Feb 15; 37(4):411-9. PubMed ID: 23278125
    [Abstract] [Full Text] [Related]

  • 11. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.
    Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I.
    Liver Transpl; 2008 May 15; 14(5):633-8. PubMed ID: 18324656
    [Abstract] [Full Text] [Related]

  • 12. Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.
    Zhou J, Fan J, Wang Z, Wu ZQ, Qiu SJ, Huang XW, Yu Y, Sun J, Xiao YS, He YF, Wang YQ, Tang ZY.
    World J Gastroenterol; 2006 May 21; 12(19):3114-8. PubMed ID: 16718799
    [Abstract] [Full Text] [Related]

  • 13. Long-term survival after recurrent hepatocellular carcinoma in liver transplant patients: clinical patterns and outcome variables.
    Kornberg A, Küpper B, Tannapfel A, Katenkamp K, Thrum K, Habrecht O, Wilberg J.
    Eur J Surg Oncol; 2010 Mar 21; 36(3):275-80. PubMed ID: 19857941
    [Abstract] [Full Text] [Related]

  • 14. Sirolimus in Liver Transplant Recipients with Hepatocellular Carcinoma: An Updated Meta-Analysis.
    Zhang ZH, Li LX, Li P, Lv SC, Pan B, He Q.
    J Invest Surg; 2019 Nov 21; 32(7):632-641. PubMed ID: 29557691
    [Abstract] [Full Text] [Related]

  • 15. Conversion to sirolimus-based maintenance immunosuppression using daclizumab bridge therapy in renal transplant recipients.
    Sundberg AK, Rohr MS, Hartmann EL, Adams PL, Stratta RJ.
    Clin Transplant; 2004 Nov 21; 18 Suppl 12():61-6. PubMed ID: 15217410
    [Abstract] [Full Text] [Related]

  • 16. Strategies of immunosuppression for liver transplant recipients with hepatocellular carcinoma.
    Castroagudín JF, Molina-Pérez E, Ferreiro-Iglesias R, Varo-Pérez E.
    Transplant Proc; 2011 Apr 21; 43(3):711-3. PubMed ID: 21486580
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
    Gomez-Martin C, Bustamante J, Castroagudin JF, Salcedo M, Garralda E, Testillano M, Herrero I, Matilla A, Sangro B.
    Liver Transpl; 2012 Jan 21; 18(1):45-52. PubMed ID: 21932373
    [Abstract] [Full Text] [Related]

  • 19. Sirolimus-based immunosuppression improves the prognosis of liver Transplantation Recipients with low TSC1/2 expression in hepatocellular carcinoma beyond the Milan Criteria.
    Ye Q, Ling S, Jiang G, Shan Q, Xu S, Zhan Q, Wu Y, Liu Y, Zheng S, Xu X.
    Eur J Surg Oncol; 2021 Oct 21; 47(10):2533-2542. PubMed ID: 33902956
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.